Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.

By N. Janzen, Hyung L. Kim, R. Figlin, A. Belldegrun. Urologic clinics of North America, 2003

769 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/972daf5f2cda34b94ec31d90aa0e462e5e3daefb

Citations in the corpus

• Pazopanib versus sunitinib in metastatic renal-cell carcinoma. (2013, unknown): “Increased total bilirubin§ 199/546 (36) 16/546 (3) 2/546 (<1) 144/541 (27) 11/541 (2) 2/541 (<1)”
• Cabozantinib versus everolimus in advanced renal cell carcinoma (2015, unknown): “Hypertension 122 (37) 49 (15) 23 (7) 10 (3)”